MAP3K2 and breast carcinoma: We previously demonstrated that MEKK2 associates with paxillin in invasive breast cancer cells, and paxillin knockdown in HEK293T cells reduced MEKK2 activity, suggesting that paxillin binds MEKK2 in multiple cell types.